IFNγ induces DNA methylation-silenced GPR109A expression via pSTAT1/p300 and H3K18 acetylation in colon cancer

Cancer Immunology Research

Volumn 3, Issue 7, 2015, Pages 795-805

  Bardhan, Kankana ^a   Paschall, Amy V ^a,b   Yang, Dafeng ^a,b   Chen, May R ^a   Simon, Priscilla S ^a,b   Bhutia, Yangzom D ^a   Martin, Pamela M ^a   Thangaraju, Muthusamy ^a   Browning, Darren D ^a   Ganapathy, Vadivel ^a   Heaton, Christopher M ^a   Gu, Keni ^c   Lee, Jeffrey R ^a,b   Liu, Kebin ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University Hospital Augusta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; GAMMA INTERFERON; GPR109A RECEPTOR; RECEPTOR; STAT1 PROTEIN; UNCLASSIFIED DRUG; EP300 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; HCAR2 PROTEIN, HUMAN; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLON; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNE SYSTEM; MOUSE; MOUSE MODEL; NONHUMAN; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN BINDING; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR SUPPRESSOR GENE; WILD TYPE; ACETYLATION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CARCINOMA; COLON TUMOR; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; TUMOR CELL LINE;

ACETYLATION; ANIMALS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DNA METHYLATION; E1A-ASSOCIATED P300 PROTEIN; GENES, TUMOR SUPPRESSOR; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 84961907115     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0164     Document Type: Article

References (50)

1. Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect dictates themechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 2012;48:612-26.
2. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res 2009;69:2826-32.
3. Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, AP IJ. International union of basic and clinical pharmacology. LXXXII: nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol Rev 2011;63:269-90.
4. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5.
5. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, Ippolito M, et al. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 2005;280:26649-52.
6. Ahmed K, Tunaru S, Offermanns S. GPR109A, GPR109B and GPR81, a family of hydroxy-carboxylic acid receptors. Trends Pharmacol Sci 2009;30:557-62.
7. Williams CL, Schilling MM, Cho SH, Lee K, Wei M, Aditi, et al. STAT4 and Tbet are required for the plasticity of IFN-gamma expression across Th2 ontogeny and influence changes in Ifng promoter DNA methylation. J Immunol 2013;191:678-87.
8. Gonsky R, Deem RL, Landers CJ, Derkowski CA, Berel D, McGovern DP, et al. Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens. Inflamm Bowel Dis 2011;17:171-8.
9. Tsukada Y, Nakamura T, Iimura M, Iizuka BE, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol 2002;97:2820-8.
10. Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, et al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002;51:379-85.
11. Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 2006;203:1391-7.
12. Arthur JC, Jobin C. The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis 2011;17:396-409.
13. Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol 2012;302:G1405-15.
14. Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFNgamma mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol 2013;182:2345-54.
15. Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer VS, Croner RS, et al. GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis 2013;34:153-62.
16. Zimmerman M, Yang D, Hu X, Liu F, Singh N, Browning D, et al. IFN-g upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells. PLoS One 2010;5:e14076.
17. Yang J, Hu X, Zimmerman M, Torres CM, Yang D, Smith SB, et al. Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells. J Immunol 2011;187:4426-30.
18. Liu F, Liu Q, Yang D, Bollag WB, Robertson K, Wu P, et al. Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3. Cancer Res 2011;71:6807-16.
19. Hu X, Yang D, Zimmerman M, Liu F, Yang J, Kannan S, et al. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Cancer Res 2011;71:2882-91.
20. Martin PM, Ananth S, Cresci G, Roon P, Smith S, Ganapathy V. Expression and localization of GPR109A (PUMA-G/HM74A) mRNA and protein in mammalian retinal pigment epithelium. Mol Vis 2009;15:362-72.
21. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, et al. Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci US A 2001;98:6680-5.
22. Xue ZT, Sjogren HO, Salford LG, Widegren B. An epigenetic mechanism for high, synergistic expression of indoleamine 2, 3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-gamma: potential therapeutic use in autoimmune diseases. Mol Immunol 2012;51:101-11.
23. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 2010;12:235-46.
24. Taylor GC, Eskeland R, Hekimoglu-Balkan B, Pradeepa MM, Bickmore WA. H4K16 acetylation marks active genes and enhancers of embryonic stem cells, but does not alter chromatin compaction. Genome Res 2013;23:2053-65.
25. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 2011;12:7-18.
26. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002;3:224-9.
27. Lin YY, Kiihl S, Suhail Y, Liu SY, Chou YH, Kuang Z, et al. Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature 2012;482:251-5.
28. Crump NT, Hazzalin CA, Bowers EM, Alani RM, Cole PA, Mahadevan LC. Dynamic acetylation of all lysine-4 trimethylated histone H3 is evolutionarily conserved and mediated by p300/CBP. Proc Natl Acad Sci U S A 2011;108:7814-9.
29. Ndlovu MN, Van Lint C, Van Wesemael K, Callebert P, Chalbos D, Haegeman G, et al. Hyperactivated NF-{kappa}B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol Cell Biol 2009;29:5488-504.
30. Genin P, Lin R, Hiscott J, Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009;29:3435-50.
31. Evans PM, Chen X, Zhang W, Liu C. KLF4 interacts with beta-catenin/TCF4 and blocks p300/CBP recruitment by beta-catenin. Mol Cell Biol 2010;30:372-81.
32. Shandilya J, Swaminathan V, Gadad SS, Choudhari R, Kodaganur GS, Kundu TK. Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancermanifestation. Mol Cell Biol 2009;29:5115-27.
33. Li TW, Ting JH, Yokoyama NN, Bernstein A, Van De Wetering M, Waterman ML. Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol 2006;26:5284-99.
34. Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 2011;30:249-62.
35. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
36. Wolf L, Harrison W, Huang J, Xie Q, Xiao N, Sun J, et al. Histone posttranslational modifications and cell fate determination: lens induction requires the lysine acetyltransferases CBP and p300. Nucleic Acids Res 2013;41:10199-214.
37. Henry RA, Kuo YM, Andrews AJ. Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4. Biochemistry 2013;52:5746-59.
38. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, Van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
39. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
40. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
41. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
42. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90.
43. Luszczek W, Cheriyath V, Mekhail TM, Borden EC. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistancewith IFN-stimulated gene expression. Mol Cancer Ther 2010;9:2309-21.
44. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 2006;24:3771-9.
45. Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Azacitidine: 10 years later. Cancer Treat Rep 1987;71:737-46.
46. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12:237-51.
47. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953-9.
48. Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009;459:113-7.
49. Steger DJ, Grant GR, Schupp M, Tomaru T, Lefterova MI, Schug J, et al. Propagation of adipogenic signals through an epigenomic transition state. Genes Dev 2010;24:1035-44.
50. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE Jr. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci U S A 1996;93:15092-6.